Top brokers name 3 ASX shares to buy today

Top brokers named Pro Medicus Limited (ASX:PME) and these ASX shares as buys. Here's why they are bullish on them…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With many brokers still taking a well-earned break over the holiday period, broker notes are few and far between right now.

In light of this, I thought I would take a look at a few that have been released over the last few weeks that remain very relevant today.

Three buy ratings that you might want to pay attention to are listed below:

finger pressing red button on keyboard labelled Buy

Image Source: Getty Images

Bapcor Ltd (ASX: BAP)

According to a note out of Citi, its analysts have retained their buy rating and lifted the price target on this auto parts retailer's shares to $8.85. The broker made the move in response to the release of a trading update from Bapcor which revealed stronger than expected sales growth in FY 2021. Citi expects this to result in a solid half year result in February. In addition to this, its analysts are fans of the company due to its defensive qualities, favourable tailwinds, and international expansion plans. The Bapcor share price is trading at $7.57 this afternoon.

Challenger Ltd (ASX: CGF)

A note out of UBS reveals that its analysts have reinstated coverage on this annuities company's shares with a buy rating and price target of $6.85. According to the note, the broker still sees value in the Challenger share price at the current level after it recovered from a selloff at the height of the pandemic. In addition, UBS believes the risks are now to the upside in respect to Challenger's earnings, especially given favourable regulatory developments. The Challenger share price is trading at $6.36 on Wednesday.

Pro Medicus Limited (ASX: PME)

Analysts at Morgans have retained their add rating and lifted the price target on this health imaging company's shares to $35.02. According to the note, the broker points out that Pro Medicus has just won another major contract in the United States. The five-year contract with MedStar Health is worth a total of A$18 million. Morgans points out that this is the first time the company has signed a major cloud-only deal. It feels this could be a sign of things to come. The Pro Medicus share price is changing hands for $32.86 today.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Bapcor, Challenger Limited, and Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Share Market News

Testing again

Read more »

Share Market News

Aaron Test 2

Read more »

Share Market News

Aaron Test

Read more »

Share Market News

JP Test

Read more »

Share Market News

JP Test

Read more »

Portrait of Discovery Fund portfolio managers Mark Devcich and Chris Bainbridge
Share Market News

Test

Portfolio managers Mark Devcich (left) and Chris Bainbridge. Image source: Discovery Fund test test

Read more »

a man in a hoodie grins slyly as he sits with his hands poised on a keyboard. He is superimposed with a graphic image of a computer screen asking for a password, suggesting he is a hacker.
Share Market News

Another ASX 200 company has been hit with a cyber incident. Here's what we know

Hackers have breached the systems of this ASX 200 company.

Read more »

a woman
Broker Notes

5 ASX 200 shares that inflation can't touch: expert

Regardless of whether you're a bull or a bear, cost pressures are a factor when buying stocks at the moment.

Read more »